Compared with EGFR-TKIs, immune checkpoint inhibitors (ICIs) have shown promising antitumor effects in non-small cell lung cancer (NSCLC) and are considered to have long-term responses that can potentially lead to cure (9–13). This evidence concerns the gene EGFR and non-small cell lung carcinoma.